A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
for Multiple Myeloma
Drug: Elranatamab
Sites in New Haven +3 more locations
Sponsor: Celgene
Sex: All·Age: 18+
Code: NCT06988488·Phase 1, Phase 2·Recruiting·Listed May 2025